Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder

Imagem de Miniatura
Arquivos
art_COSTA_Application_of_Lipidomics_in_Psychiatry_PlasmaBased_Potential_Biomarkers_2023.PDF (9.53 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
RICA, Larissa B.
ZANDONADI, Flavia S.
SUSSULINI, Alessandra
Citação
METABOLITES, v.13, n.5, article ID 600, 15p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In this study, we obtained a lipidomic profile of plasma samples from drug-naive patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls. The sample cohort consisted of 30 BD and 30 SZ patients and 30 control individuals. An untargeted lipidomics strategy using liquid chromatography coupled with high-resolution mass spectrometry was employed to obtain the lipid profiles. Data were preprocessed, then univariate (t-test) and multivariate (principal component analysis and orthogonal partial least squares discriminant analysis) statistical tools were applied to select differential lipids, which were putatively identified. Afterward, multivariate receiver operating characteristic tests were performed, and metabolic pathway networks were constructed, considering the differential lipids. Our results demonstrate alterations in distinct lipid pathways, especially in glycerophospholipids, sphingolipids and glycerolipids, between SZ and BD patients. The results obtained in this study may serve as a basis for differential diagnosis, which is crucial for effective treatment and improving the quality of life of patients with psychotic disorders.
Palavras-chave
bipolar disorder, biomarkers, lipidomics, plasma, schizophrenia
URI
https://observatorio.fm.usp.br/handle/OPI/54794
Referências
  1. Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403
  2. Alonso J, 2011, MOL PSYCHIATR, V16, P1234, DOI 10.1038/mp.2010.101
  3. [Anonymous], 2016, SOJ PSYCHOL, DOI [DOI 10.15226/2374-6874/3/2/00131, 10.15226/2374-6874/3/2/00131]
  4. APA - AMERICAN PSYCHIATRIC ASSOCIATION, 2014, DSM 5 MAN DIAGN EST
  5. Arvindakshan M, 2003, BIOL PSYCHIAT, V53, P56, DOI 10.1016/S0006-3223(02)01443-9
  6. Ayano G., 2016, J SCHIZOPHRENIA RES, V3, P2, DOI 10.15226/2374-6874/3/2/00131
  7. Balanza-Martinez V, 2011, EXPERT REV NEUROTHER, V11, P1029, DOI [10.1586/ERN.11.42, 10.1586/ern.11.42]
  8. Basu S, 2017, BIOINFORMATICS, V33, P1545, DOI 10.1093/bioinformatics/btx012
  9. Bell CC., 1994, DIAGN STAT MAN MENT, V272, P828, DOI [10.1001/jama.1994.03520100096046, DOI 10.1001/JAMA.1994.03520100096046]
  10. Brand SJ, 2015, CURR NEUROPHARMACOL, V13, P324, DOI 10.2174/1570159X13666150307004545
  11. Brum M, 2023, WORLD J BIOL PSYCHIA, V24, P564, DOI 10.1080/15622975.2023.2169348
  12. Brunkhorst-Kanaan N, 2019, METABOLISM, V95, P65, DOI 10.1016/j.metabol.2019.04.002
  13. Burton TCJ, 2023, AM J CLIN NUTR, V117, P717, DOI 10.1016/j.ajcnut.2023.01.018
  14. Charlson FJ, 2018, SCHIZOPHRENIA BULL, V44, P1195, DOI 10.1093/schbul/sby058
  15. Chiappelli J, 2014, JAMA PSYCHIAT, V71, P761, DOI 10.1001/jamapsychiatry.2014.243
  16. Coman C, 2016, MOL CELL PROTEOMICS, V15, P1453, DOI 10.1074/mcp.M115.053702
  17. Costa AC, 2019, SCHIZOPHR RES, V206, P468, DOI 10.1016/j.schres.2018.11.010
  18. Gao J, 2010, BIOINFORMATICS, V26, P971, DOI 10.1093/bioinformatics/btq048
  19. Gattaz WF, 2011, J PSYCHIATR RES, V45, P1617, DOI 10.1016/j.jpsychires.2011.07.005
  20. GATTAZ WF, 1987, BIOL PSYCHIAT, V22, P421, DOI 10.1016/0006-3223(87)90164-8
  21. GATTAZ WF, 1995, SCHIZOPHR RES, V16, P1, DOI 10.1016/0920-9964(94)00060-L
  22. GATTAZ WF, 1994, FORTSCHR NEUROL PSYC, V62, P489, DOI 10.1055/s-2007-1002352
  23. Ghosh S, 2017, J PSYCHIATR RES, V95, P135, DOI 10.1016/j.jpsychires.2017.08.009
  24. de la Fuente AG, 2018, J PHARMACEUT BIOMED, V154, P138, DOI 10.1016/j.jpba.2018.02.046
  25. Gil-de-la-Fuente A, 2019, J PROTEOME RES, V18, P797, DOI 10.1021/acs.jproteome.8b00720
  26. Goodwin GM, 2008, EUR NEUROPSYCHOPHARM, V18, P535, DOI 10.1016/j.euroneuro.2008.03.003
  27. Gorgens KA., 2011, ENCY CLIN NEUROPSYCH, P2410, DOI 10.1007/978-0-387-79948-3_2011
  28. Grande I, 2016, LANCET, V387, P1561, DOI 10.1016/S0140-6736(15)00241-X
  29. Guo L, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.802710
  30. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  31. Harper KN, 2011, SCHIZOPHR RES, V128, P30, DOI 10.1016/j.schres.2011.01.009
  32. Janoutova J, 2016, NEUROENDOCRINOL LETT, V37, P1
  33. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  34. Kuhl C, 2012, ANAL CHEM, V84, P283, DOI 10.1021/ac202450g
  35. Libiseller G, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0562-8
  36. Lin S, 2023, CLIN CHIM ACTA, V541, DOI 10.1016/j.cca.2023.117252
  37. Liu JC, 2023, MEDICINA-LITHUANIA, V59, DOI 10.3390/medicina59020413
  38. McEvoy J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068717
  39. Pang ZQ, 2022, NAT PROTOC, V17, P1735, DOI 10.1038/s41596-022-00710-w
  40. Phillips ML, 2013, LANCET, V381, P1663, DOI 10.1016/S0140-6736(13)60989-7
  41. Quintero M, 2019, ADV EXP MED BIOL, V1118, P271, DOI 10.1007/978-3-030-05542-4_14
  42. Ribeiro HC, 2017, PSYCHIAT RES, V258, P268, DOI 10.1016/j.psychres.2017.08.039
  43. Ribeiro HC, 2022, METABOLOMICS, V18, DOI 10.1007/s11306-022-01924-5
  44. Ross BM, 2007, LIPIDS HEALTH DIS, V6, DOI 10.1186/1476-511X-6-21
  45. Rowland TA, 2018, THER ADV PSYCHOPHARM, V8, P251, DOI 10.1177/2045125318769235
  46. Schwarcz R, 2001, BIOL PSYCHIAT, V50, P521, DOI 10.1016/S0006-3223(01)01078-2
  47. Sethi S, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv096
  48. Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
  49. Skinner E.R., 2002, BRAIN LIPIDS DISORDE, VVolume 35
  50. Smesny S, 2014, MOL PSYCHIATR, V19, P317, DOI 10.1038/mp.2013.7
  51. Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
  52. Sud M, 2016, NUCLEIC ACIDS RES, V44, pD463, DOI 10.1093/nar/gkv1042
  53. Talib LL, 2021, EUR ARCH PSY CLIN N, V271, P1593, DOI 10.1007/s00406-021-01246-y
  54. Tasic L, 2017, SCHIZOPHR RES, V185, P182, DOI 10.1016/j.schres.2016.12.024
  55. Teixeira AL, 2019, EXPERT REV NEUROTHER, V19, P67, DOI 10.1080/14737175.2019.1550361
  56. Tessier C, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.142
  57. Veselkov KA, 2011, ANAL CHEM, V83, P5864, DOI 10.1021/ac201065j
  58. Wang F, 2022, MEDICINA-LITHUANIA, V58, DOI 10.3390/medicina58111509
  59. World Health Organization, 1993, ICD 10 CLASSIFICATIO
  60. Yao JK, 2000, SCHIZOPHR RES, V42, P7, DOI 10.1016/S0920-9964(99)00095-X
  61. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
  62. Yuan N, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0570-y

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Carregar mais